Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

Low-dose naltrexone does not provide real clinical benefit for patients with fibromyalgia compared to placebo, according to a clinical trial.

Emerging research says the steroids aren’t a major driver of gestational diabetes, but impacts vary depending on the patient.

More nurses regularly take on second shifts but as the practice becomes normalized, is this best for patients?

A large population-based study finds that bone marrow oedema and symphyseal cleft signs are common incidental findings on ...

New research suggests that time and aging change how people deal with regrets. Here’s what it could mean for doctors.

Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic ...

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical ...

Learning through art history that obesity once denoted prosperity, strength, and beauty, may help healthcare providers treat ...

Disease activity, organ involvement, and treatment choice all shape infection risk in lupus and rheumatoid arthritis, with ...

A longitudinal study shows that optimal AUDIT-C cutoff values for predicting alcohol-attributable harm vary significantly by ...

Romania’s children under 5 are experiencing the worst of Europe’s measles outbreaks. Are new policies sufficient to encourage ...